Movement Alert｜Repligen Falls 6.33% in Regular Trading, Market Cautious After BioLife Solutions Acquisition Completion

Market Focus

Yesterday

On October 6, Repligen fell 6.33% in regular trading, trading at $177.505/share, with turnover of $124 million.

The decline followed the company's formal announcement of completing its acquisition of BioLife Solutions, a deal valued at approximately $1.5 billion in cash and stock. Under the terms, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, implying a per-share valuation of about $31 for BioLife, a premium of roughly 6.2% to its prior close.

The acquisition provides Repligen with BioLife's cell preservation technology, cell processing tools, and higher-margin consumables business, aimed at strengthening its position in the cell therapy market. Separately, S&P Dow Jones Indices announced that Freshworks will replace BioLife Solutions in the S&P SmallCap 600 effective October 8, following the completion of the transaction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1159631810"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159631810\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159631810?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-07 00:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159631810","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Repligen Falls 6.33% in Regular Trading, Market Cautious After BioLife Solutions Acquisition Completion","media":"Market Focus","content":"<p><p>On October 6, Repligen fell 6.33% in regular trading, trading at $177.505/share, with turnover of $124 million.</p><p>The decline followed the company's formal announcement of completing its acquisition of BioLife Solutions, a deal valued at approximately $1.5 billion in cash and stock. Under the terms, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, implying a per-share valuation of about $31 for BioLife, a premium of roughly 6.2% to its prior close.</p><p>The acquisition provides Repligen with BioLife's cell preservation technology, cell processing tools, and higher-margin consumables business, aimed at strengthening its position in the cell therapy market. Separately, S&P Dow Jones Indices announced that Freshworks will replace BioLife Solutions in the S&P SmallCap 600 effective October 8, following the completion of the transaction.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Repligen Falls 6.33% in Regular Trading, Market Cautious After BioLife Solutions Acquisition Completion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Repligen Falls 6.33% in Regular Trading, Market Cautious After BioLife Solutions Acquisition Completion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-07 00:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 6, Repligen fell 6.33% in regular trading, trading at $177.505/share, with turnover of $124 million.</p><p>The decline followed the company's formal announcement of completing its acquisition of BioLife Solutions, a deal valued at approximately $1.5 billion in cash and stock. Under the terms, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, implying a per-share valuation of about $31 for BioLife, a premium of roughly 6.2% to its prior close.</p><p>The acquisition provides Repligen with BioLife's cell preservation technology, cell processing tools, and higher-margin consumables business, aimed at strengthening its position in the cell therapy market. Separately, S&P Dow Jones Indices announced that Freshworks will replace BioLife Solutions in the S&P SmallCap 600 effective October 8, following the completion of the transaction.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGEN","symbol_name":"Repligen Corporation","start_time":0,"source_url":"","article_id":"1159631810","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159631810","pubTimestamp":1791304084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 6, Repligen fell 6.33% in regular trading, trading at $177.505/share, with turnover of $124 million.The decline followed the company's formal announcement of completing its acquisition of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGEN":"Repligen Corporation"},"translate_title":"走势警报|Repligen常规交易下跌6.33%，BioLife Solutions收购完成后市场谨慎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGEN":1},"content_text":"On October 6, Repligen fell 6.33% in regular trading, trading at $177.505/share, with turnover of $124 million.The decline followed the company's formal announcement of completing its acquisition of BioLife Solutions, a deal valued at approximately $1.5 billion in cash and stock. Under the terms, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, implying a per-share valuation of about $31 for BioLife, a premium of roughly 6.2% to its prior close.The acquisition provides Repligen with BioLife's cell preservation technology, cell processing tools, and higher-margin consumables business, aimed at strengthening its position in the cell therapy market. Separately, S&P Dow Jones Indices announced that Freshworks will replace BioLife Solutions in the S&P SmallCap 600 effective October 8, following the completion of the transaction.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}